Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

18.09.2020 | short review | Ausgabe 4/2020 Open Access

memo - Magazine of European Medical Oncology 4/2020

Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?

memo - Magazine of European Medical Oncology > Ausgabe 4/2020
Dr. Elisabeth Gasser, PD Dr. Pamela Kogler, Dr. Andreas Lorenz, PD Dr. Reinhold Kafka-Ritsch, Univ. Prof. Dr. Dietmar Öfner, Assoc. Professor PD Dr. med. univ. Alexander Perathoner
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Peritoneal carcinomatosis from colorectal cancer is associated with a poor prognosis and is usually treated with systemic chemotherapy and immunotherapy alone. In patients with isolated peritoneal carcinomatosis (PC) without nonperitoneal metastases, however, cytoreductive surgery (CRS) has been shown to significantly improve outcome and to achieve even cure in selected patients in combination with systemic therapy. The additional use of a hyperthermic intraperitoneal chemotherapy (HIPEC) is primarily indicated to control microscopical residual tumor tissue in the peritoneal cavity after successful CRS. Another more recent option is the application of an adjuvant HIPEC to prevent peritoneal carcinomatosis in high risk patients with pT4 cancer or perforated cancer at the time of or after primary surgery. The aim of this short review is to highlight the corresponding available literature and assess the role of CRS and HIPEC in the context of modern chemotherapy and immunotherapy.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2020

memo - Magazine of European Medical Oncology 4/2020 Zur Ausgabe